Company profile

Clasp Therapeutics, Inc.

Privately held: no public share price (Privately held, VC-backed; $150M Series A March 2024 led by Catalio, Third Rock and Novo Holdings. [resolved 2026-08-05 by resolve-null-is-public; source: https://www.clasptx.com/press-release-publications/clasp-therapeutics-launches-with-150-million-to-pioneer-precision-immuno-oncology-using-next-generation-t-cell-engagers-with-unparalleled-specificity-ymmx7]) · United States

Assets

(1 total)
1Total Assets
0Approved
0Phase 3 / Filed
1Phase 1–2 / Early
1Diseases
Showing 1 of 1 assets
Target & Modality
CLSP-5282
Phase 1
KRAS G12V peptide presented by HLA-A*03:01Small molecule
Non-Small Cell Lung Cancer

Upcoming events

Research

Unlock the company readout calendar

Research includes estimated primary-completion dates, earnings report dates, and 'What to watch' trial analysis across this company’s pipeline.

Financial reports

Research

Unlock sourced financial history

Research includes quarterly, interim and annual revenue, R&D, cash and burn figures linked to the underlying company reports.

Educational data tool. Figures are sourced from company filings and press releases: see each row's filing link. Share price is delayed (~15min) and refreshed periodically, not a real-time feed.